Microbiome Therapeutics Innovation Group

Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial

Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial :: Vedanta Biosciences, Inc. Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial Jul 23, 2024 Appointments support ongoing Phase 2 COLLECTiVE202 trial of VE202, pivotal Phase 3 RESTORATiVE303 trial of VE303 and planning for commercial stage activity CAMBRIDGE, Mass., July 23, 2024 – Vedanta Bioscienc...

The human microbiome is one of the new frontiers of medicine that has the potential to benefit patients suffering from numerous diseases afflicting millions of patients and consuming billions of dollars of healthcare resources.

About the Microbiome About the Microbiome THE MICROBIOME The human microbiome provides metabolic and synthetic functions essential to the human health, including regulating the immune system and aiding in digestion. It also provides protection against colonization and invasion by potential microbial pathogens. Through a...

Siolta Therapeutics' STMC-103H allergic disease onset prevention study, is Siolta’s proof of concept study aimed at stopping allergic disease before it starts by targeting early intervention of infants at high risk for developing allergic diseases. Learn more:

Pipeline - Siolta Therapeutics Our unique platform is designed to address multiple targets across a wide range of diseases. With clinical studies underway for allergic diseases, we are broadening our portfolio in the “maternal-infant axis” by advancing programs for recurrent bacterial vaginosis and necrotizing enterocolitis. ...

Genetic Analysis As is dedicated to delivering new and innovative diagnostic solutions to the rapidly growing human microbiome market. Find out more:

Home - Genetic Analysis Supplying high quality diagnostics to the microbiome market Genetic Analysis AS is a researched driven diagnostic company dedicated to deliver new and innovative diagnostic solutions to the rapidly growing human microbiome market Read more GA has developed and commercialized a standardized diagnosti...

MTIG's coalition of companies is leading the R&D of FDA-approved microbiome therapeutics and microbiome-based products to address unmet medical needs, improve clinical outcomes, and reduce health care costs. Learn more about our work:

Home Through a collective voice, the MTIG membership works together to enhance the regulatory, investment, and commercial environment to accelerate microbiome therapeutic product development and expand availability of life-changing and life-saving FDA approved microbiome therapies to patients. . The huma...

BiomeSense’s pioneering GutLabTM automated laboratory system and MetaBiomeTM bioinformatics platform are the first-ever solution to provide continuous, at-home tracking & analysis of the microbiome. Learn more:

Technology | BiomeSense, Inc. BiomeSense is developing novel technologies to enable the collection, storage, and analysis of daily human gut microbiome profiles.

Microbiome therapeutics hold significant therapeutic potential to prevent, treat, or cure a wide variety of diseases or conditions associated with the . Learn about the differences between probiotic supplements and FDA regulated microbiome therapeutics.

All pharmaceutical and biotechnology companies pursuing regulatory approvals for microbiome therapeutics and microbiome-based products are eligible for consideration of membership in MTIG. Learn more on our website:

Home Through a collective voice, the MTIG membership works together to enhance the regulatory, investment, and commercial environment to accelerate microbiome therapeutic product development and expand availability of life-changing and life-saving FDA approved microbiome therapies to patients. . The huma...

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science | Seres Therapeutics The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts.

Vedanta's VE303 is a potential first-in-class LBP candidate consisting of a defined bacterial consortium designed for the prevention of recurrent C. difficile infection (rCDI). Vedanta recently enrolled the first patient in the pivotal Phase 3 RESTORATiVE303 study of VE303I.

Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection :: Vedanta Biosciences, Inc. Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection May 21, 2024 VE303 is an orally administered, potential first-in-class live biotherapeutic product candidate being developed to prevent recurrence of Clos...

The microbiome directly or indirectly affects physiologic and immunologic functions. An imbalance or disruption of this complex ecologic system can lead to “dysbiosis”, which is associated with a multitude of chronic diseases and some infections. Learn more:

About the Microbiome About the Microbiome THE MICROBIOME The human microbiome provides metabolic and synthetic functions essential to the human health, including regulating the immune system and aiding in digestion. It also provides protection against colonization and invasion by potential microbial pathogens. Through a...

Siolta Therapeutics combines clinical data, bioinformatics, and world-class microbial science to develop synergistic combinations of bacteria that target disease-specific mechanisms of action. Learn about Siolta's pipeline here:

Pipeline - Siolta Therapeutics Our unique platform is designed to address multiple targets across a wide range of diseases. With clinical studies underway for allergic diseases, we are broadening our portfolio in the “maternal-infant axis” by advancing programs for recurrent bacterial vaginosis and necrotizing enterocolitis. ...

Did you know that atopic dermatitis (AD) patients have been found to have a different microbial composition in their skin and gut? Microbiome therapeutics currently in development have the potential to address microbiome composition and influence the incidence and severity of AD.

Seres' SER-155 is a multifunctional consortium of commensal bacteria designed to augment microbiome functions which are associated with better survival and lower rates of infection and GvHD in patients undergoing stem cell transplantation.

Our Programs Our microbiome therapeutics represent an entirely new class of medicines with promise across a range of diseases.

MTIG promotes regulatory policies and legislation that support innovation in the microbiome arena. Learn about our policy priorities here:

MTIG Priorities MTIG Priorities Policy Priorities Through the strength of its collective membership, MTIG promotes regulatory policies and legislation that support innovation in the microbiome arena. Currently MTIG is focused on advancing the following policy initiatives: Streamlining the regulatory process to incr...

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates https://bit.ly/3JOZ3qK

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024 https://bit.ly/4a3dEtn

FDA-approved microbiome therapeutics have vast potential to help treat a wide range of diseases and conditions across gastrointestinal, neurological, immunological, oncological, and other indications. Learn more:

About the Microbiome About the Microbiome THE MICROBIOME The human microbiome provides metabolic and synthetic functions essential to the human health, including regulating the immune system and aiding in digestion. It also provides protection against colonization and invasion by potential microbial pathogens. Through a...

Bacthera offers a range of technologies for the Live Biotherapeutic Product industry that supports and de-risks the CMC development for their customers. Learn more about their technologies here:

Technologies Bacthera offers a range of technologies for the Live Biotherapeutic Product industry that supports and de-risks the CMC development of our customers. The challenges in Live Biotherapeutic Product manufacturing are manifold. Independently if it is strains that have to be handled in a strict anaerobe....

Vedanta Biosciences to Present at Upcoming Investor Conferences

Vedanta Biosciences to Present at Upcoming Investor Conferences :: Vedanta Biosciences, Inc. Vedanta Biosciences to Present at Upcoming Investor Conferences Apr 29, 2024 CAMBRIDGE, MA, April 29, 2024 – Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that members of its execu...

Unlike f***l transplants, Vedanta's bacterial consortia therapeutics are defined drug compositions produced from clonally isolated bacteria that can trigger targeted immune responses. Learn how Vedanta's bacterial consortia can robustly shift the gut ecosystem.

How Our Drugs Work :: Vedanta Biosciences, Inc. In the near future, your doctor may prescribe you drugs made of live bacterial consortia. These drugs have the potential of colonizing the human intestine naturally and repairing microbiome alterations that drive disease.

Evidence has shown a link between the human microbiome, host immunity and response to melanoma therapy. Learn about the potential of microbiome therapeutics to help treat melanoma less invasively and with fewer side effects:

Siolta Therapeutic's Precision Symbiotics Platform leverages the Company's internal expertise in microbiome data analysis, machine learning, anaerobic microbiology, and translational studies to rationally design and optimize multi-strain live biotherapeutics for the prevention and treatment of diseases of high unmet medical need.

Our Platform - Siolta Therapeutics Machine learning and network analysis are applied to high-resolution clinical microbiome data to identify and prioritize therapeutic candidates. Clinical data generated from internal development and external observational studies are collated for increased discovery power.

Rebiotix, a Ferring Company's, REBYOTA is the first and only single-dose, FDA approved microbiome-based treatment to keep recurrent C. diff infection from coming back. Learn more about REBYOTA here:

What is REBYOTA? | REBYOTA® (f***l microbiota, live- jslm) Learn more about REBYOTA®, the 1st and only single-dose FDA-approved microbiome-based treatment for prevention of recurrent C. diff infection, after antibiotics.

Microbiome therapeutic products have the potential to treat a wide range of diseases in clinical settings including C. diff infection, IBD, asthma and more. Learn about the differences between probiotic supplements and FDA regulated microbiome therapeutics here:

Genetic Analysis' GA-map® Dysbiosis test is a valuable tool as a supplement for patient treatment and in clinical research, making it possible to generate profiles of a person’s gut microbiota and connect the profile to the patients’ health conditions.

The GA-map® Dysbiosis Test Lx – Your front-end solution to microbiota profiling - Genetic Analysis The GA-map® Dysbiosis Test Lx Your front-end solution to microbiota profiling The GA-map® Dysbiosis test is a valuable tool as a supplement for patient treatment and in clinical research. The test makes it possible to generate profiles of a person’s gut microbiota and connect the profile to the...

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT | Seres Therapeutics The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts.

BiomeSense's integrated solution transforms the entire microbiome ecosystem, starting with continuous data generation & analysis and ending with the first large, standardized microbiome database - providing the tools to power the entire microbiome field. https://bit.ly/3gRwZre

Home | Chicago | BiomeSense, Inc. BiomeSense is developing novel technologies to enable the collection, storage, and analysis of daily human gut microbiome profiles.

The microbiome field has grown exponentially in the past several years including the FDA approval of the first two microbiota-based products. Learn more about the vast and exciting potential of microbiome therapeutics:

About the Microbiome About the Microbiome THE MICROBIOME The human microbiome provides metabolic and synthetic functions essential to the human health, including regulating the immune system and aiding in digestion. It also provides protection against colonization and invasion by potential microbial pathogens. Through a...

FDA-approved microbiome therapeutics have vast potential to help treat a wide range of diseases and conditions across gastrointestinal, neurological, immunological, oncological, and other indications. Learn more about microbiome therapeutics here:

About the Microbiome About the Microbiome THE MICROBIOME The human microbiome provides metabolic and synthetic functions essential to the human health, including regulating the immune system and aiding in digestion. It also provides protection against colonization and invasion by potential microbial pathogens. Through a...